A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 409 participants.
Also called NCT06660173
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 409 participants
- Sponsor
- Registry
-
NCT06660173 -
2024-513539-25-00
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Austria, Greece, Hong Kong SAR China, Hungary, Italy, Japan, Poland, Puerto Rico, Romania, South Korea, Spain, Sweden, Taiwan
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06660173. Randomized; double masking; primary purpose treatment. Start 2024-11-07 (actual); primary completion 2025-10-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- Maridebart Cafraglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct06660173- Content hash
ed220e20262b92ffd02491a4a0e77804f0d5392cee1372b3c42cc0b5461def99